EpiVax wins $324K NIH grant to improve Pompe disease treatment

By
-
EPIVAX HAS WON a $324,000 grant to develop a web tool that will quickly determine whether Pompe disease patients are at risk for an immune response to enzyme replacement therapy.
EPIVAX HAS WON a $324,000 grant to develop a web tool that will quickly determine whether Pompe disease patients are at risk for an immune response to enzyme replacement therapy.
PROVIDENCE — EpiVax Inc. has received a $324,980 Small Business Innovation Research grant to continue development of a web-based test for people at risk of life-threatening immune responses to enzyme replacement treatments for Pompe disease, coinciding with the company’s 20th anniversary. Pompe disease is an inherited metabolic disorder caused by the deficiency of the acid alpha-glucosidase…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

If you have already logged in and are still seeing this message, please refresh the page as your browser is caching the old content.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

RELATED ARTICLESMORE FROM AUTHOR

No posts to display